3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
3
Glioblastoma
2
Breast Neoplasms
2
Recurrence
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Astrocytoma
1
Interventions
Magnetic Resonance Spectroscopy
19
Radiosurgery
16
Radiotherapy
14
Specimen Handling
11
Pemetrexed
8
Paclitaxel
6
Erlotinib Hydrochloride
6
Docetaxel
6
Carboplatin
6
Bevacizumab
5
pembrolizumab
4
Temozolomide
4
Spinal Puncture
4
Cisplatin
4
osimertinib
3
Taxes
3
Nivolumab
3
Gemcitabine
3
Gefitinib
3
Filgrastim
3
Drug Therapy
3
trametinib
2
selpercatinib
2
sapanisertib
2
motexafin gadolinium
2
epothilone B
2
dabrafenib
2
X-Rays
2
Vorinostat
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
cabazitaxel
×
CNS
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled